Shares of 22nd Century Group dropped during regular market hours, sliding from a previous close of $1.93 to about $1.595, a decline of -17.36%. The slide extends the stock's post-reverse-split decline: a 1-for-58 reverse stock split took effect Nov. 5 to restore Nasdaq's $1 minimum-bid compliance, and selling resumed the next session amid ongoing dilution.
Ispire Technology is scheduled to report results for its fiscal first quarter of 2027 (the period ended September 30, 2026) on Monday, November 9, 2026, before the market opens. Wall Street consensus calls for a net loss of $0.03 per share, an improvement from the $0.06 loss posted in the same quarter a year earlier.
Universal Corporation reported second quarter fiscal 2027 revenue of $621.8 million , down 18% from $754.2 million a year earlier and below the consensus estimate of about $630.1 million. Diluted earnings per share (EPS) came in at $0.50 , down 63% from $1.36 in the prior-year quarter and short of the $0.58 analysts expected.
BTI (British American Tobacco) trades at a materially lower valuation with a higher dividend yield, while PM (Philip Morris International) commands a premium multiple for faster smoke-free growth. Both companies are pivoting from combustible cigarettes toward reduced-risk products — pouches, vapes, and heated tobacco — but PM is further along, with smoke-free products now exceeding 40% of revenue.
22nd Century Group is scheduled to report its third quarter 2026 results on November 16, 2026, after releasing preliminary figures in late October. Preliminary results point to net revenue of about $4.8 million, up 66% from $2.9 million in the second quarter of 2026.
Both BTI and PM are pivoting from combustible cigarettes toward smoke-free nicotine, but PM is far further along, with smoke-free products exceeding 40% of revenue versus roughly 20% for BTI . BTI offers a notably higher dividend yield (roughly 5–6%) and a lower forward valuation, while PM carries richer multiples but faster earnings growth and a rising payout.
22nd Century Group shares fell roughly 92% over the past 30 days, sliding from about $0.91 to about $0.07. The decline was amplified by aggressive equity issuance: an at-the-market offering expanded the share count more than fivefold in a single day in late October.
Smokeless transition is the core growth driver: New Categories (vapour, modern oral, and heated tobacco) revenue rose 18% at constant currency in the first half of 2026, with modern oral up nearly 66%, positioning BAT to outgrow a structurally declining cigarette industry. U.S. regulatory tailwind is emerging: The U.S. Food and Drug Administration's (FDA) prioritisation guidance and enforcement against illicit vapour could shift demand back to legal channels, supporting BAT's planned nationwide Velo Max rollout and select Vuse flavour launches in the second half of 2026.
The central price target for British American Tobacco p.l.c. (BTI) is $70, based on the average analyst price target of roughly $70.37 reported across major data providers. With the stock recently trading near $61.52, reaching $70 would require a gain of about 14%.
British American Tobacco (BTI) rose roughly 16.9% over the past 30 days, climbing from about $52.64 to $61.52 as of the most recent close. The rebound followed an early-October sell-off linked to a dividend ex-date, guidance set toward the lower end of ranges, and a sharp rise in global bond yields.
U.S. entry is the defining catalyst: Pending U.S. Food and Drug Administration (FDA) authorizations for IQOS ILUMA and ZYN Ultra could open Philip Morris's largest unaddressed growth opportunity. Smoke-free is scaling fast: Smoke-free products already generate roughly 41%–43% of revenue, shifting the company's mix toward higher-margin categories.
The central target used here is $230 , roughly 10% above Philip Morris International's latest closing price of about $208.79. This objective is drawn from public discussion — specifically the top of the current analyst price-target range — not from a calculated consensus, because the average analyst target sits too close to the market price to be meaningful.
Philip Morris International (PM) shares climbed roughly 11% over the past 30 days, rising from about $187 to approximately $209. The advance followed third-quarter 2026 results that beat analyst estimates, including adjusted EPS of $2.36 and net revenue of $11.4 billion.
Major catalysts ahead: a full national rollout of on! PLUS nicotine pouches, new flavor extensions, a disciplined re-entry of the NJOY ACE e-vapor device, and a potential modernization of the FDA's premarket tobacco product application (PMTA) framework. Strategic positioning: Altria's dominant U.S. combustible franchise — led by Marlboro — continues to fund a transition toward smoke-free products, though the growth story has increasingly centered on the on! nicotine pouch brand.
The central target of $85 is not an analyst-consensus figure. It reflects a technical and psychological milestone above the 52-week high rather than the average of published analyst price targets. The average analyst price target sits near $70, below the recent share price, so the analyst-based method could not be used; the $85 level is used here as a fallback objective.
Altria Group (MO) shares climbed roughly 15.7% over the last 30 days, rising from about $67.34 on September 30 to near $77.90. The advance accelerated after Altria's October 29 third-quarter 2026 report, which beat consensus with adjusted EPS of $1.52 and revenue of $6.13 billion.
British American Tobacco reported its first-half 2026 (H1 2026) results on July 30, 2026, with group revenue up 2.9% on a constant-currency basis. Adjusted diluted earnings per share (EPS, a measure of profit attributable to each share) rose 7.9%, supported by lower net finance costs and strong cash conversion.
Altria Group reported third-quarter net revenues of $6.13 billion , up 1.0% year over year, while revenues net of excise taxes rose 3.6% to $5.44 billion. Adjusted diluted earnings per share (EPS) came in at $1.52 , up 4.8% from the prior year and a penny above the analyst consensus of $1.51.
Different asset types: MO is a single high-dividend tobacco company, while VOO is a passively managed exchange-traded fund (ETF) tracking the S&P 500 Index across roughly 500 large-cap U.S. stocks. Return profile diverges: MO has delivered strong year-to-date gains driven by pricing power and its smoke-free transition, while VOO offers broad, diversified market exposure with roughly 13% year-to-date appreciation.
Altria (MO) is a U.S.-focused tobacco leader that leans on pricing power and high shareholder returns, while Philip Morris International (PM) is a global operator betting on smoke-free products such as IQOS and ZYN. Both stocks have posted strong year-to-date gains, but PM has outpaced MO in recent market activity as its smoke-free revenue mix expands.